Skip to main content
. Author manuscript; available in PMC: 2021 Sep 15.
Published in final edited form as: Eur J Pharmacol. 2020 Jul 11;883:173362. doi: 10.1016/j.ejphar.2020.173362

Fig. 5-. DHCA/Mal-gluc did not induce changes in regulation of Nrxn1 and 3 total expression or alternative splicing in PFC after CVS.

Fig. 5-

Quantitative real-time PCR for total Nrxn1/3 and alternative splicing variants (splicing site 4, SS4) for male (A-C) and female mice (D-F). No significant changes were found in total mRNA expression or alternative splicing variants (SS4) of NRXN 1 and 3 in male or female mice. Female mice, One-way ANOVA: F 3,37 = 1.59, P= 0.218 for NRX1; F 3,39= 0.318 , P=0.729 for Nrxn1 SS4+; F 3,36 = 0.84 , P= 0.439 for Nrxn1 SS4−; F 3, 40 =1.31 , P=0.28 for Nrxn3; F 3,40 = 0.12 , P= 0.87 for Nrxn3 SS4+; F 3,40 = 2.83 , P= 0.070 for Nrxn3 SS4−. Male mice, One-way ANOVA: F 3,38= 4.7, P= 0.86 for NRX1; F 3,40 = 0.88 , P=0.41 for Nrxn1 SS4+ ; F 3,40= 3.10 , P=0.056 for Nrxn1 SS4−; F 3,35= 0.623 , P= 0.603 for Nrxn3; F 3,37 =2.41, P= 0.1014 for Nrxn3 SS4+; F 3,37 =3.1 P =0.054 for Nrxn3 SS4−. Nrxn mRNA values were normalized vs GADPH as internal control and expressed as fold changes relative to non-treated controls (vehicle). Mean ± S.E.M are represented (n=8-10 animals/group).